Class information for:
Level 1: HER 2//HER2 TESTING//POLYSOMY 17

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
6712 1378 35.3 86%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
451 15419 HER 2//TRASTUZUMAB//LAPATINIB

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 HER 2 Author keyword 51 13% 27% 373
2 HER2 TESTING Author keyword 20 67% 1% 18
3 POLYSOMY 17 Author keyword 19 80% 1% 12
4 HER 2 NEU Author keyword 19 15% 8% 114
5 TOP2A Author keyword 18 47% 2% 29
6 CISH Author keyword 18 39% 3% 36
7 HERCEPTEST Author keyword 17 68% 1% 15
8 CHROMOGENIC IN SITU HYBRIDIZATION Author keyword 17 36% 3% 37
9 CHROMOSOME 17 POLYSOMY Author keyword 14 100% 1% 7
10 HER2 GENE Author keyword 12 58% 1% 14

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 HER 2 51 13% 27% 373 Search HER+2 Search HER+2
2 HER2 TESTING 20 67% 1% 18 Search HER2+TESTING Search HER2+TESTING
3 POLYSOMY 17 19 80% 1% 12 Search POLYSOMY+17 Search POLYSOMY+17
4 HER 2 NEU 19 15% 8% 114 Search HER+2+NEU Search HER+2+NEU
5 TOP2A 18 47% 2% 29 Search TOP2A Search TOP2A
6 CISH 18 39% 3% 36 Search CISH Search CISH
7 HERCEPTEST 17 68% 1% 15 Search HERCEPTEST Search HERCEPTEST
8 CHROMOGENIC IN SITU HYBRIDIZATION 17 36% 3% 37 Search CHROMOGENIC+IN+SITU+HYBRIDIZATION Search CHROMOGENIC+IN+SITU+HYBRIDIZATION
9 CHROMOSOME 17 POLYSOMY 14 100% 1% 7 Search CHROMOSOME+17+POLYSOMY Search CHROMOSOME+17+POLYSOMY
10 HER2 GENE 12 58% 1% 14 Search HER2+GENE Search HER2+GENE

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 HER 2 NEU STATUS 85 75% 4% 62
2 ARCHIVAL TISSUE SAMPLES 73 75% 4% 52
3 HER 2 NEU GENE AMPLIFICATION 64 51% 7% 90
4 HERCEPTEST 58 88% 2% 28
5 POLYSOMY 17 49 94% 1% 17
6 CISH 47 88% 2% 22
7 CLINICAL ONCOLOGY COLLEGE 40 45% 5% 68
8 ANTHRACYCLINE BASED THERAPY 33 67% 2% 29
9 CHROMOSOME 17 POLYSOMY 24 68% 2% 21
10 PREDICTIVE MARKERS 22 35% 4% 51

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy 2015 2 62 68%
HER2 testing: Current status and future directions 2014 10 60 73%
Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies 2012 42 26 65%
HER2 testing and its predictive utility in anti-HER2 breast cancer therapy 2015 1 78 63%
HER2 in Breast Cancer: A Review and Update 2014 11 73 48%
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine 2009 318 362 25%
HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis 2011 30 54 74%
The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice 2014 4 21 81%
Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis 2014 4 28 68%
HER2 discordance between primary and metastatic breast cancer: Assessing the clinical impact 2013 9 53 83%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 UK EXTERNAL QUAL ASSESSMENT EME 6 80% 0.3% 4
2 ENDOCRINE CANC GRP 6 27% 1.5% 20
3 TISSUE TUMOR BANK 4 75% 0.2% 3
4 UNITE TRANSFERT CANCEROL CLIN 3 100% 0.2% 3
5 CLIN PATHOL L11 2 50% 0.2% 3
6 UK NEQAS 2 33% 0.3% 4
7 TRANSLAT SECT 1 21% 0.4% 6
8 BANK FROZEN TISSUES GENET SPECIMEN 1 50% 0.1% 2
9 GRP ETUD TEURS PRONOST IMMUNOHISTOCHIM CANC SE 1 100% 0.1% 2
10 MED INTERMT HEALTHCARE 1 50% 0.1% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000235548 C ERBB 2//HER 2 NEU//P185
2 0.0000225128 TRASTUZUMAB//LAPATINIB//PERTUZUMAB
3 0.0000201552 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2//ADVANCED METASTATIC DISEASE//ANTI EGF RECEPTOR ANTIBODY
4 0.0000167598 TISSUE MICROARRAYS//LAYERED EXPRESSION SCANNING//TISSUE MICROARRAYS TMAS
5 0.0000137076 ONCOTYPE DX//TRIPLE NEGATIVE BREAST CANCER//TRIPLE NEGATIVE
6 0.0000114000 ER ICA//IMMUNOCYTOCHEMICAL ASSAY//PROGESTERONE RECEPTORS
7 0.0000074785 INFLAMMATORY BREAST CANCER//NEOADJUVANT CHEMOTHERAPY//LOCALLY ADVANCED BREAST CANCER
8 0.0000072151 CLIN BREAST CARE PROJECT//16Q243//CHROMOSOMAL SCANNING
9 0.0000067527 ANTIGEN RETRIEVAL//HEAT INDUCED ANTIGEN RETRIEVAL//JOURNAL OF HISTOTECHNOLOGY
10 0.0000049619 METHACARN//FFPE//HOPE TECHNIQUE